EU orphan designations
Every medicine the European Commission has designated as an orphan medicine for a rare disease, on the EMA's recommendation, with its current status.
Matching designations
4 matches| Substance | Intended use | Status | Designated |
|---|---|---|---|
| Hydrocortisone hydrogen succinate EU/3/21/2452 |
Prevention of bronchopulmonary dysplasia | Withdrawn | 21 Jun 2021 |
| hydrocortisone EU/3/07/441 22 clinical trials → |
Treatment of adrenal insufficiency | Withdrawn | 20 Mar 2007 |
| hydrocortisone EU/3/06/372 22 clinical trials → |
Treatment of adrenal insufficiency | Expired | 22 May 2006 |
| hydrocortisone EU/3/05/296 22 clinical trials → |
Treatment of congenital adrenal hyperplasia | Active (positive) | 27 Jul 2005 |
How this page is built
Every row is copied from the EMA's orphan designations data, reproduced with acknowledgement of the source. Each substance links to its official EMA page.
- EMA orphan designations data (JSON report) ↗ active substance, intended use, EU designation number, date of designation, status and the link to each designation page
A daily job downloads the EMA's orphan designations JSON report and lists every designation, newest first. No AI drafting and no editorial pass. See our editorial standards. The the EMA data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.